[go: up one dir, main page]

CY1114988T1 - Βενζοδιαζεπινη αναστολεας bromodomain - Google Patents

Βενζοδιαζεπινη αναστολεας bromodomain

Info

Publication number
CY1114988T1
CY1114988T1 CY20141100124T CY141100124T CY1114988T1 CY 1114988 T1 CY1114988 T1 CY 1114988T1 CY 20141100124 T CY20141100124 T CY 20141100124T CY 141100124 T CY141100124 T CY 141100124T CY 1114988 T1 CY1114988 T1 CY 1114988T1
Authority
CY
Cyprus
Prior art keywords
bromodomain
benzodiazepin
risk
compound
therapy
Prior art date
Application number
CY20141100124T
Other languages
English (en)
Inventor
Romain Luc Marie Gosmini
Olivier Mirguet
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42667965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114988(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0919433A external-priority patent/GB0919433D0/en
Priority claimed from GBGB1010509.6A external-priority patent/GB201010509D0/en
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1114988T1 publication Critical patent/CY1114988T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε μια ένωση βενζοδιαζεπίνης του τύπου (Ι), μεθόδους για την παρασκευή αυτής, φαρμακευτικές συνθέσεις που περιέχουν με τέτοια ένωση και χρήση αυτής στην θεραπεία.
CY20141100124T 2009-11-05 2014-02-18 Βενζοδιαζεπινη αναστολεας bromodomain CY1114988T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0919433A GB0919433D0 (en) 2009-11-05 2009-11-05 Novel compounds
GBGB1010509.6A GB201010509D0 (en) 2010-06-22 2010-06-22 Novel compounds
EP10740654.8A EP2496580B1 (en) 2009-11-05 2010-08-06 Benzodiazepine bromodomain inhibitor

Publications (1)

Publication Number Publication Date
CY1114988T1 true CY1114988T1 (el) 2016-12-14

Family

ID=42667965

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100124T CY1114988T1 (el) 2009-11-05 2014-02-18 Βενζοδιαζεπινη αναστολεας bromodomain
CY20161100172T CY1117479T1 (el) 2009-11-05 2016-03-01 Βενζοδιαζεπινικος αναστολεας bromodomain

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20161100172T CY1117479T1 (el) 2009-11-05 2016-03-01 Βενζοδιαζεπινικος αναστολεας bromodomain

Country Status (33)

Country Link
US (3) US9023842B2 (el)
EP (3) EP3037423B1 (el)
JP (1) JP5524343B2 (el)
KR (1) KR101424989B1 (el)
CN (1) CN102762569B (el)
AU (1) AU2010314395B2 (el)
BR (1) BR112012010706A2 (el)
CA (1) CA2779355C (el)
CL (1) CL2012001178A1 (el)
CO (1) CO6540003A2 (el)
CR (1) CR20120283A (el)
CY (2) CY1114988T1 (el)
DK (2) DK2496580T3 (el)
DO (1) DOP2012000114A (el)
EA (1) EA020390B1 (el)
ES (3) ES2652304T3 (el)
HK (1) HK1220188A1 (el)
HR (2) HRP20140107T1 (el)
HU (1) HUE026421T2 (el)
IL (2) IL219090A0 (el)
MA (1) MA33803B1 (el)
ME (1) ME02360B (el)
MX (1) MX2012005295A (el)
MY (1) MY160456A (el)
NZ (1) NZ599258A (el)
PE (1) PE20121181A1 (el)
PH (1) PH12012500894A1 (el)
PL (2) PL2722334T3 (el)
PT (2) PT2496580E (el)
RS (2) RS53179B (el)
SI (2) SI2496580T1 (el)
SM (2) SMT201400024B (el)
WO (1) WO2011054553A1 (el)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
DK2496582T3 (en) * 2009-11-05 2016-03-21 Glaxosmithkline Llc Benzodiazepine-BROMDOMAeNEINHIBITOR.
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
PL2571503T3 (pl) 2010-05-14 2015-06-30 Dana Farber Cancer Inst Inc Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CA2870931A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Isoindolone derivatives
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
EP2884983B1 (en) * 2012-08-16 2017-10-04 GlaxoSmithKline LLC Benzodiazepines for treating small cell lung cancer
ES2628005T3 (es) 2012-08-16 2017-08-01 Bayer Pharma Aktiengesellschaft 2,3-Benzodiazepinas
US9663523B2 (en) 2012-09-28 2017-05-30 Bayer Pharma Aktiengesellschaft BET protein-inhibiting 5-aryltriazoleazepines
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2961411A4 (en) * 2013-02-28 2016-11-23 Univ Washington METHOD FOR TREATING INFECTIONS WITH HUMAN CYTOMAL GALOVIRUS AND DISEASES WITH BROMDOMAIN DISEASES
JP2016512524A (ja) 2013-03-11 2016-04-28 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
EP2970285B1 (en) 2013-03-11 2019-04-17 AbbVie Inc. Fused tetracyclic bromodomain inhibitors
JP6280573B2 (ja) * 2013-03-14 2018-02-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としてのフロピリジン
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
KR20150135359A (ko) * 2013-03-14 2015-12-02 컨버진 엘엘씨 브로모도메인-함유 단백질의 억제를 위한 방법 및 조성물
ES2909778T3 (es) 2013-03-15 2022-05-10 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de proteína BET para su uso en el tratamiento de una enfermedad proliferativa en combinación con un inhibidor de Janus quinasas
EP2792355A1 (en) 2013-04-17 2014-10-22 Albert-Ludwigs-Universität Freiburg Compounds for use as bromodomain inhibitors
EA027139B1 (ru) 2013-04-26 2017-06-30 Бейджин, Лтд. Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
WO2015002754A2 (en) 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
ES2635560T3 (es) 2013-07-08 2017-10-04 Incyte Holdings Corporation Heterociclos tricíclicos como inhibidores de la proteína NET
MX2016001037A (es) 2013-07-25 2016-11-10 Dana Farber Cancer Inst Inc Inhibidores de factores de transcripción y usos.
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US9428513B2 (en) 2013-11-07 2016-08-30 Boehringer Ingelheim International Gmbh Triazolopyrazine
MX379463B (es) 2013-11-08 2025-03-10 Dana Farber Cancer Inst Inc Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
GB201320994D0 (en) * 2013-11-28 2014-01-15 Univ Dundee Enzyme function probes
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
JP2017504650A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015120393A1 (en) 2014-02-10 2015-08-13 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
CA2938742A1 (en) * 2014-02-10 2015-08-13 Salk Institute For Biological Studies Increasing storage of vitamin a, vitamin d and/or lipids
WO2015121230A1 (de) * 2014-02-14 2015-08-20 Bayer Pharma Aktiengesellschaft 9-substituierte 2,3-benzodiazepine
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
PL3129378T3 (pl) 2014-04-09 2020-03-31 Kainos Medicine, Inc. Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu
SG10201809353TA (en) 2014-04-23 2018-11-29 Incyte Corp 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
HUE043441T2 (hu) 2014-06-20 2019-08-28 Constellation Pharmaceuticals Inc 2-((4S)-6-(4-klórfenil)-l-metil-4H-benzo[c]izoxazolo[4,5-e]azepin-4-il)acetamid kristályos formái
NO2719005T3 (el) 2014-07-28 2018-01-20
CN106573915B (zh) * 2014-08-01 2020-12-25 纽韦卢森公司 针对布罗莫结构域有活性的化合物
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
JP2017530155A (ja) * 2014-10-02 2017-10-12 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 化合物
EP3212654B1 (en) 2014-10-27 2020-04-08 Tensha Therapeutics, Inc. Bromodomain inhibitors
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
SG11201704089UA (en) 2014-12-05 2017-06-29 H Lee Moffitt Cancer Ct & Res Bromodomain inhibitor as adjuvant in cancer immunotherapy
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
CA2974153A1 (en) 2015-02-03 2016-08-11 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
RU2752729C2 (ru) 2015-05-18 2021-07-30 Сумитомо Даиниппон Фарма Онколоджи, Инк. Пролекарства альвоцидиба, имеющие повышенную биодоступность
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AR105124A1 (es) 2015-06-26 2017-09-06 Tensha Therapeutics Inc Tratamiento de carcinoma de la línea media nut
JP6765622B2 (ja) 2015-07-17 2020-10-07 日本光電工業株式会社 救命支援装置
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
KR20180081507A (ko) * 2015-10-02 2018-07-16 다나-파버 캔서 인스티튜트 인크. 브로모도메인 저해제와 관문 차단의 조합 요법
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
EP3693369A3 (en) 2016-04-15 2020-09-09 AbbVie Inc. Bromodomain inhibitors
TWI830533B (zh) 2016-06-20 2024-01-21 美商英塞特公司 Ｂｅｔ抑制劑之結晶固體形式
US10918647B2 (en) 2016-07-26 2021-02-16 University Of Southern California Selective bromodomain inhibition of fungal Bdf1
WO2018086605A1 (zh) 2016-11-10 2018-05-17 山东罗欣药业集团股份有限公司 一种含氮大环类化合物、其制备方法、药物组合物及应用
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
CN107759607B (zh) * 2017-11-29 2019-08-23 上海万巷制药有限公司 具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法
CN113490499A (zh) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR20230026461A (ko) 2020-06-23 2023-02-24 제넨테크, 인크. 거대고리 화합물 및 이의 사용 방법
GB202016977D0 (en) 2020-10-26 2020-12-09 In4Derm Ltd Compounds
JP2023538405A (ja) 2020-12-01 2023-09-07 成都苑▲東▼生物制▲薬▼股▲ふん▼有限公司 新規ｎ－複素環ｂｅｔブロモドメイン阻害剤、その調製方法及び医薬応用
MX2024000238A (es) 2021-06-29 2024-01-30 Tay Therapeutics Ltd Derivados de pirrolopiridona utiles en el tratamiento del cancer.
US20250382308A1 (en) 2022-04-19 2025-12-18 Nuevolution A/S Compounds active towards bromodomains
EP4558224A1 (en) 2022-07-21 2025-05-28 Tay Therapeutics Limited Pyrroles and imidazoles as bet protein inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3610848A1 (de) * 1986-04-01 1987-10-15 Boehringer Ingelheim Kg Neue 1,4-diazepine
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
CA2120939A1 (en) 1991-10-11 1993-04-15 Tetsuya Tahara Therapeutic agent for osteoporosis and diazepine compound
JPH06128257A (ja) 1992-10-13 1994-05-10 Yoshitomi Pharmaceut Ind Ltd ピリドジアゼピン化合物
EP0730596A4 (en) 1993-11-22 1997-07-30 Merck & Co Inc BENZODIAZEPINE
IT1285567B1 (it) 1996-02-21 1998-06-18 Alfa Chem Ital Nuovo processo per la sintesi del nabumetone
EP0934940A1 (en) * 1996-06-12 1999-08-11 Japan Tobacco Inc. Cytokine production inhibitors, triazepine compounds, and intermediates thereof
PT989131E (pt) 1996-09-13 2003-03-31 Mitsubishi Pharma Corp Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais
JPH11228576A (ja) * 1997-12-10 1999-08-24 Japan Tobacco Inc アポトーシス抑制剤
ES2388434T3 (es) 2003-11-03 2012-10-15 Glaxo Group Limited Dispositivo de administración de fluido
CN1739788A (zh) 2004-03-31 2006-03-01 新加坡国立大学 Trip－br功能的调节和治疗增殖性紊乱的方法
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
TWI447120B (zh) 2005-05-30 2014-08-01 Mitsubishi Tanabe Pharma Corp 噻吩并三唑并苯二氮呯化合物、其醫藥上之用途
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
CA2779355A1 (en) 2011-05-12
HUE026421T2 (en) 2016-05-30
CN102762569B (zh) 2015-04-01
JP5524343B2 (ja) 2014-06-18
EP3037423A1 (en) 2016-06-29
EP3037423B1 (en) 2017-09-20
RS54592B1 (sr) 2016-08-31
NZ599258A (en) 2014-05-30
BR112012010706A2 (pt) 2016-03-29
DK2496580T3 (da) 2014-02-24
SI2496580T1 (sl) 2014-02-28
ES2652304T3 (es) 2018-02-01
ES2563057T3 (es) 2016-03-10
HK1175458A1 (en) 2013-07-05
CY1117479T1 (el) 2017-04-26
CR20120283A (es) 2012-08-14
KR20120099250A (ko) 2012-09-07
PE20121181A1 (es) 2012-09-13
AU2010314395B2 (en) 2015-04-09
PL2496580T3 (pl) 2014-06-30
IL219090A0 (en) 2012-06-28
WO2011054553A1 (en) 2011-05-12
HK1191012A1 (en) 2014-07-18
EP2722334A1 (en) 2014-04-23
ME02360B (me) 2016-06-20
KR101424989B1 (ko) 2014-07-31
HK1220188A1 (en) 2017-04-28
US20120220573A1 (en) 2012-08-30
US9023842B2 (en) 2015-05-05
SI2722334T1 (sl) 2016-03-31
PH12012500894A1 (en) 2022-03-09
SMT201600081B (it) 2016-04-29
CL2012001178A1 (es) 2012-10-05
CO6540003A2 (es) 2012-10-16
SMT201400024B (it) 2014-07-07
EA020390B1 (ru) 2014-10-30
ES2446647T3 (es) 2014-03-10
HRP20140107T1 (hr) 2014-04-25
EP2496580B1 (en) 2013-12-11
EP2496580A1 (en) 2012-09-12
HRP20160119T1 (hr) 2016-02-26
EA201290183A1 (ru) 2012-12-28
PT2496580E (pt) 2014-02-21
PT2722334E (pt) 2016-03-11
MX2012005295A (es) 2012-06-19
PL2722334T3 (pl) 2016-06-30
EP2722334B1 (en) 2016-01-13
DOP2012000114A (es) 2012-08-15
MA33803B1 (fr) 2012-12-03
JP2013510107A (ja) 2013-03-21
CA2779355C (en) 2018-01-16
US20170197972A1 (en) 2017-07-13
IL235983B (en) 2018-01-31
RS53179B (sr) 2014-06-30
DK2722334T3 (en) 2016-03-07
MY160456A (en) 2017-03-15
IL235983A0 (en) 2015-01-29
AU2010314395A1 (en) 2012-05-24
CN102762569A (zh) 2012-10-31
US20150210706A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CY1114988T1 (el) Βενζοδιαζεπινη αναστολεας bromodomain
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1119684T1 (el) Αντι-ιικες ενωσεις
CY1116578T1 (el) Αναστολεις της bromodomain και χρησεις αυτων
CY1117424T1 (el) Βενζοδιαζεπινικος αναστολεας bromodomain
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
CY1115994T1 (el) Φαρμακευτικες τυποποιησεις οι οποιες περιεχουν προσδεματα υποδοχεα ντοπαμινης
CY1118061T1 (el) Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1111354T1 (el) Συστασεις αναστολεα ddp iv
UA110612C2 (uk) Похідні 1-аміно-2-циклопропілетилборонової кислоти
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201170832A1 (ru) Пуриновые соединения
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
CY1113551T1 (el) Υποκατεστημενες ενωσεις νικοτιναμιδιου και η χρησιμοποιηση τους σε φαρμακα